These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31346595)

  • 1. Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder.
    Springer SA
    Clin Infect Dis; 2020 Jun; 70(12):2703-2705. PubMed ID: 31346595
    [No Abstract]   [Full Text] [Related]  

  • 2. It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs.
    Barocas JA
    Clin Infect Dis; 2021 Apr; 72(8):1401-1403. PubMed ID: 32166311
    [No Abstract]   [Full Text] [Related]  

  • 3. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
    Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
    J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phylogenetic Analysis of Hepatitis C Virus Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Ganova-Raeva L; Punkova LT; Agyemang L; Sue A; Ramachandran S; Khudyakov Y; Litwin AH
    J Infect Dis; 2020 Jul; 222(3):488-498. PubMed ID: 32150621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland.
    Falcato L; Bernardini C; Bruggmann P
    Int J Drug Policy; 2021 Oct; 96():103434. PubMed ID: 34511311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
    Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J
    Clin Infect Dis; 2021 Apr; 72(8):1392-1400. PubMed ID: 32166305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
    Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
    Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.
    Norton BL; Akiyama MJ; Zamor PJ; Litwin AH
    Infect Dis Clin North Am; 2018 Jun; 32(2):347-370. PubMed ID: 29778260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use.
    Bota S; Razpotnik M; Hucke F; Urak C; Flatscher K; Peck-Radosavljevic M
    Wien Klin Wochenschr; 2021 Jul; 133(13-14):641-646. PubMed ID: 34032930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs.
    Rosenthal ES; Silk R; Mathur P; Gross C; Eyasu R; Nussdorf L; Hill K; Brokus C; D'Amore A; Sidique N; Bijole P; Jones M; Kier R; McCullough D; Sternberg D; Stafford K; Sun J; Masur H; Kottilil S; Kattakuzhy S
    Clin Infect Dis; 2020 Oct; 71(7):1715-1722. PubMed ID: 32009165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.
    Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J
    Clin Infect Dis; 2020 May; 70(11):2369-2376. PubMed ID: 31300820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.
    Stevens ER; Nucifora KA; Hagan H; Jordan AE; Uyei J; Khan B; Dombrowski K; des Jarlais D; Braithwaite RS
    Clin Infect Dis; 2020 Jun; 70(12):2652-2662. PubMed ID: 31400755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort.
    Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Dore GJ; Matthews GV;
    Int J Drug Policy; 2021 Oct; 96():103422. PubMed ID: 34426040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
    Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AY; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL;
    Ann Intern Med; 2016 Nov; 165(9):625-634. PubMed ID: 27537841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Call to Action: HCV Treatment of People Who Inject Drugs in the United States.
    Norton BL; Litwin AH
    Clin Infect Dis; 2020 May; 70(11):2366-2368. PubMed ID: 31513706
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
    Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study.
    Heo M; Pericot-Valverde I; Niu J; Norton BL; Akiyama MJ; Nahvi S; Arnsten JH; Litwin AH
    J Viral Hepat; 2023 Feb; 30(2):172-175. PubMed ID: 36197920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.